ADIM
TARO

Alpha DNA Investment Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Alpha DNA Investment Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-53
Closed -$3K – 698
2021
Q1 		$3K Buy
53
+15
+39% +$1.14K ﹤0.01% 532
2020
Q4 		$2K Buy
+38
New +$2.44K ﹤0.01% 496

Other funds holding TARO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alpha DNA Investment Management's TARO Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2021, closing a stake of 53 shares — an estimated $3K sold.

Alpha DNA Investment Management first reported a position in TARO in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 76 funds tracked by Wall St. Rank hold TARO as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 53 Taro Pharmaceutical Industries Ltd. shares in Q2 2021, an estimated $3K.
  • Alpha DNA Investment Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Taro Pharmaceutical Industries Ltd. position peaked at $3K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.